In contrast, participants in the post hoc analysis were from the same cohort as the clinical trial where a GLP-1 agonist (Liraglutide) was used to evaluate its effect on body weight and pain in patients with knee osteoarthritis who were overweight or obese. The gene discussed is GLP1R; the disease is osteoarthritis, knee.